Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | DPP4 | P27487 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.71 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.71 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.71 |
| ▸ | GAPDH | P04406 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.71 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.71 |
| ▸ | STAT6 | P42226 | 1/20 | 0.71 |
| ▸ | PI4KA | P42356 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.71 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.71 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.71 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.71 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8616982 | 0.93 | ADORA3 (0.72) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL8179689 | 0.92 | ADORA3 (0.71) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL23754814 | 0.88 | ADORA3 (0.59) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL23414488 | 0.87 | ADORA3 (0.77) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL4658306 | 0.87 | ADORA3 (0.77) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL7555711 | 0.87 | LMNA (0.57) | ADORA3ADORA1ADORA2AADORA2BSLC29A1 | |
| SCHEMBL15755555 | 0.86 | ADORA3 (0.75) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL23547979 | 0.86 | ADORA3 (0.75) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL21418864 | 0.86 | ADORA3 (0.75) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 | |
| SCHEMBL16359953 | 0.86 | ADORA3 (0.75) | ADORA3ADORA1SMN1; SMN2DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260043027-A1 | LINKER, COMPOUND INCLUDING LINKER, METHOD OF PREPARING COMPOUND, USE OF LINKER, AND METHOD OF DELIVERING OLIGONUCLEOTIDES THROUGH LINKER | SYNERK BIOTECH LTD (HK) | 2026-02-12 | — | — | US | disclosed |
| WO-2025133603-A1 | LIQUID-PHASE PROCESS FOR PREPARING OLIGONUCLEOTIDES | Exactmer Limited (GB) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025053766-A2 | DINUCLEOTIDE MONOPHOSPHATE DERIVATIVE, THE NUCLEIC ACID DERIVATIVE CONTAINING IT, AND THE METHOD OF OBTAINING IT | SIEĆ BADAWCZA ŁUKASIEWICZ PORT POLSKI OŚRODEK ROZWOJU TECHNOLOGII (PL) | 2025-03-13 | — | — | WO | disclosed |
| EP-4103578-A1 | NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | Uniwersytet Warszawski (PL) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021162566-A1 | NOVEL MRNA 5'-END CAP ANALOGS MODIFIED WITHIN PHOSPHATE RESIDUES, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2021-08-19 | — | — | WO | disclosed |
| CN-107532162-A | Compositions and methods for editing nucleic acids in cells using oligonucleotides | 托德·M·伍尔夫 | 2018-01-02 | — | — | CN | disclosed |
| EP-1340766-B1 | Optically active DNA probe having phosphonic diester linkage | TOSOH CORP (JP) | 2008-11-12 | — | — | EP | disclosed |
| US-20050074760-A1 | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures | RIBOZYME PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| EP-0959077-B1 | Optically active DNA probe having phosphonic diester linkage | TOSOH CORP (JP) | 2004-09-01 | — | — | EP | disclosed |
| EP-1340766-A1 | Optically active DNA probe having phosphonic diester linkage | Tosoh Corporation (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6586238-B1 | Modified ribozymes; useful for cleavage of RNA or single-stranded DNA; Resistance to exonuclease degradation | RIBOZYME PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | disclosed |
| EP-1108724-A2 | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6211354-B1 | SINGLE-STRANDED DNA PROBE HAVING CHIRAL LINKER, AN O,O-DINUCLEOTIDE-2-AMINOETHYLPHOSPHONIC ACID, ATTACHED IN THE MIDDLE AND JOINED TO A FLORESCENT INTERCALATIVE DYE; ONE-STEP HYBRIDIZATION; NO ISOLATION STEP | TOSCH CORPORATION (JP) | 2001-04-03 | — | — | US | disclosed |
| US-5998203-A | PARTICULARLY USEFUL FOR ENZYMATIC CLEAVAGE OF RNA OR SINGLE-STRANDED DNA. | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0959077-A1 | Optically active DNA probe having phosphonic diester linkage | Tosoh Corporation (JP) | 1999-11-24 | — | — | EP | disclosed |
| EP-0886641-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1997026270-A2 | SYNTHESIS OF METHOXY NUCLEOSIDES AND ENZYMATIC NUCLEIC ACID MOLECULES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-07-24 | — | — | WO | disclosed |
| US-4845205-A | 2,N6 -disubstituted and 2,N6 -trisubstituted adenosine-3'-phosphoramidites | INSTITUT PASTEUR (FR) | 1989-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074760-A1 | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures | RNGTT, MTAP, RNASEL | ADORA3 2216/4885ADORA1 3137/4885SMN1; SMN2 3195/4885 |
| US-20260043027-A1 | LINKER, COMPOUND INCLUDING LINKER, METHOD OF PREPARING COMPOUND, USE OF LINKER, AND METHOD OF DELIVERING OLIGONUCLEOTIDES THROUGH LINKER | SSU72, NSUN2, RNMT | ADORA3 1351/4885ADORA1 2232/4885SMN1; SMN2 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.